Novo Nordisk A/S (NYSE:NVO)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
NVO Weekly Chart

Old Forum Content for NVO

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: ...
    All that said, the stock has been squashed back down to pre-run-up levels at the June low where it is now desperately battling to hold on. I could see it go even lower from here - today or in the following days. I make no predictions from here, thou ...
  • ReneeH: @woodman $VKTX $NVO $LLY it's a love hate here, when they move they move....both directions unfortunately. I feel ya.
  • woodman: @ReneeH $VKTX $NVO $LLY - Trading vs investing, too. You can trade anything generally (though see below for biotech, specifically), but investing is a different thing. I think investing in small/mid cap biotech, particularly with no approved drugs, i ...
  • ReneeH: @woodman $VKTX $NVO $LLY 100% agree, thank you. I'm much more of a trader vs investor. With biotech, I've had a few great hits and a lot of disappointment. Very tricky to time just right.
  • woodman: ...
    Finally, as the review suggests, comparing VKTX's 12% weight loss at just 13 weeks vs. $LLY's oral version which achieved 11% at 72 weeks and $NVO's oral which achieved 14% at 64 weeks is - on its face - an unfair comparison. But they were Phase 3 d ...
  • joelsg1: @woodman $VKTX $LLY $NVO $LLY is preparing to flood the zone with their pill even before approval. I think it's a mistake to discount the no-needle convenience of the daily pill, but once massive supply is available, it's pretty much Game Over for the competitors, unless there's a huge difference in tolerability. And even on that last point, millions of people continue to take statins because they see immediate improvement in their cholesterol numbers, despite the fact that for many their feet, ankles, leg muscles hurt.
  • woodman: @joelsg1 $VKTX $LLY $NVO - Funny thing is, I know many on the injectibles, and not one of them complains about it. It's such a nothing burger. At least not from a pain standpoint. But yes swallowing a pill is more convenient than dealing with syringes and vials or even autoinjectors.
  • Bs7518: @woodman $VKTX $LLY $NVO Thanks for sharing the article I take the shot once a week and your right the pain is nothing so the pill is import to me but as an investor it is.
  • billyzeke: $LLY's loss is $NVo's gain....there's a weight joke in there somewhere. I have no position in either.
  • traderbren: @billyzeke $LLY $NVo - yeah, there probably is. Interesting to note that $NVO is up on the day while $LLY is tanking on the news. $NVO's pill performs better than $LLY.
  • woodman: @ZMan2 $HIMS - Conversely, $NVO is a disaster.
  • ZMan2: @woodman $HIMS $NVO Great minds think alike. I was thinking the exact same thing $NVOs loss was $HIMS gain.
  • StockMarketMentor: ...
    As for stocks, might want to watch SoFi ($SOFI) for a breakout related to earnings, but this type of trade is always risky because everything tends to be factored in at the open. Consider Novo Nordisk ($NVO) on a rebound after issuing weak guidance ...
  • peterd: @StockMarketMentor $SOFI $NVO $PYPL $SMH $NVDA $SMCI $AMD Earnings next Tuesday from $SMCI which is on the ATL.
  • DAN: @peterd $SOFI $NVO $PYPL $SMH $NVDA $SMCI $AMD YEp. Thanks!
  • StockMarketMentor: ...
    Hims & Hers ($HIMS) [or Them & They as some call it ($TNT)] is getting poleaxed this morning after Novo Nordisk ($NVO) ended its partnership due to illegal mass compounding in China and a deceptive marketing campaign intended to hoodwink cus ...
  • AndStars: @woodman @Bert953 The GLP-1 and GIP agonists are truly game changers. Not merely cosmetic. Truly improve the health directly by weight loss, but also in so many ways beyond mere weight loss. Cardiovascular disease. Diabetes. Depression. Anxiety. Kidney disease. OSA (obstructive sleep apnea). Peripheral neuropathy. To name a few. Besides increasing life span and quality of life, these drugs will be shown to save huge amounts on healthcare costs. Even at their high prices (which with time will come down) the cost vs. benefit is a no brainer. One reason why $LLY and $NVO can justify. Time for the health insurance industry ($UNH, et al) to get on board and cover this. It will reduce their costs by preventing expenditures on the above preventable disease states.
  • woodman: @AndStars $LLY $NVO $UNH - I totally agree.
  • traderbren: $NVO - Yikes, someone was asleep at the wheel! Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor According to Saynor, “Novo never filed a patent in Canada,”and he says he has no idea why, since “It's the second-largest semaglutide market in the world,” which is the name of the compound that is sold under the brand names Ozempic, Rybelsus, and Wegovy.
  • camaro69: $NVO having a nice day
  • DavidK: $SEPN- big investment from $NVO. Looking at chart this might have more upside to fill . I know nothing about the company . I do have a bear put spread on $NVO so that’s not working out .
  • woodman: @DavidK $SEPN $NVO - https://www.investors.com/news/technology/novo-nordisk-obesity-deal-septerna-gpcr/
  • DavidK: $SEPN- looks like market not liking the partnership with $NVO . I bought some here .
  • woodman: @DavidK $SEPN $NVO - First Rule of Thumb in Biotech (SEPN here): Sell the good news.
  • DavidK: @woodman $SEPN $NVO ipo was around 16-18 . In Feb they pulled a drug trial in phase 1 and it tanked . $NVO must think they have something to invest like this . Worth a shot here based on it moved from 6-12 and change over night now down in the 8.60 range. Tree shaking and traders taking that quick pop money as you stated .
  • woodman: @DavidK $SEPN $NVO - The weight-loss drug makers are looking for new molecules. $NVO is losing the GLP-1 battle to $LLY's Zepbound (current best in class). Orals are coming, as are new molecules. It's an ever-evolving area and new assets are needed. Companies mostly need to find them outside their own walls. $2 billion is inexpensive for these assets, if remotely promising. Many drug MFR CEOS want deals under $5 billion; under $3 billion even better.
  • DavidK: @woodman $SEPN $NVO $LLY moving up into the close as I expected.
  • DavidK: @woodman $LLY $MCK $CAH the big issue being brought up is the exorbitant cost for the exact same drug in the USA as opposed to other countries . He mention Ozempic. which is a $NVO drug .
  • woodman: @DavidK $LLY $MCK $CAH $NVO - Bringing down the price of GLP-1s would be a huge victory for consumers. The more testing they do and the more data that come in on them, the more they are finding these to be wonder drugs with so many benefits - not just weight loss itself. $LLY's Zepbound (aka Mounjaro for diabetes), which is superior to $NOV's Wegovy (aka Ozempic for diabetes) is currently $449 per month for private pay without insurance coverage for 5mg, which is on the low end of the dosing (it starts at 2.5mg, which is meant as a starter from which to move up) and goes to 15mg. Insurance doesn't cover it for the great majority of consumers.
  • joelsg1: @woodman $LLY $MCK $CAH $NVO $NOV Interesting that now the GLP-1 stocks have reversed and moved higher. Maybe they know this executive order lacks teeth, or that they'll make it back with volume, $AMGN, $LLY and $HIMS.
  • woodman: @woodman $LLY $MCK $CAH $NVO $NOV - EDIT: Zepbound is $499 (not $449) per month for the 5 mg dose via LillyDirect Self Pay Program.
  • joelsg1: @woodman $LLY $MCK $CAH $NVO $NOV Or duct tape mouth when hungry, much cheaper :)
  • woodman: @joelsg1 $LLY $MCK $CAH $NVO $NOV - For some, yes. For others, they simply can't lose the weight despite working out, maintaining good nutrition, and not over-eating. Plus, like I said, there are so many additional health benefits to taking the drug.
  • woodman: $HIMS - party may over for obesity drug compounders (though HIMS compounds drugs other than obesity drugs) with FDA's official announcement $NVO's Ozempic/Wegovy shortages (like $LLY's Zepbound/Mounjaro) are over, though I have a friend who said CVS told him there was some kind of problem filling his Zepbound prescription due to lack of supply, which is odd.
  • joelsg1: $HIMS Losing weight as FDA lifts supply constraints on $NVO and $LLY weight loss drugs, Death knell for copycat compounders IMO. Might short any bounce.
  • marklesparkle: @joelsg1 $HIMS $NVO $LLY Joel now that has a ring to it death knell for copycat compounders
  • joelsg1: @marklesparkle $HIMS $NVO $LLY New punk band?
  • nnkumar13: $NVO seems to be moving
  • woodman: @joelsg1 $HIMS $NVO $LLY - Good call.
  • Dig44north: @joelsg1 $HIMS $NVO $LLY $LLY is strong, climbing the upper bb on the 5 min chart. Looking to take out my 900 cc
  • woodman: @DavidG $VKTX - Lots of theories, because, you know, there's always a reason for a move, right? I don't know anything specifically attributed to this move that I'd call reliable. I saw some references to VK2735 and VK0214 trial recruitments/starts/co ...
  • woodman: @woodman $VKTX $ALT $LLY $GPCR $HIMS $NVO - Just saw this. Cowen GLP-1 Market: The Pipeline Expands - Global GLP-1 sales in 2030 could reach $139B, up from our $101B forecast a little over a year ago. The market is maturing but accruing health outcomes data should broaden access and maintain momentum.
  • woodman: @woodman $VKTX $ALT $LLY $GPCR $HIMS $NVO - Interesting that VKTX has dropped to a $3.8B market cap, and ended 2024 with a decent cash position of $903 million. But it is running multiple trials now, so it will have to burn a lot.
  • joelsg1: @woodman $GPCR I did notice headline yesterday that FDA approved $NVO's Ozempic for kidney disease, the first GLP-1 approved for such use, so maybe that.
  • woodman: @joelsg1 $GPCR $NVO - That's awesome!
  • Wolf: $NVO Up 12% on phase 1 data on weight loss Drug.
  • woodman: $NVO into the gap.
  • Henry: $NVO Getting hammered in pm. New weight loss drug did not achieve 25% weight loss target. I'd take the 20% they did get.
  • traderbren: @Henry $NVO - agreed. It looks like $LLY is gaining weight as a result. ;-)
  • woodman: @Henry $NVO - $VKTX up on this news, I guess. But VKTX is hitting a major supply area at $48-$56, and I don't think has any major catalysts upcoming, so I could see it stall in that zone.
  • Henry: @woodman $NVO $VKTX I thought yesterday was VKTX's day to have a study fail
  • woodman: @Henry $NVO $VKTX Everyone gets a turn at the wheel.
  • woodman: @kenb $ARDX - Good point. This is a company with 2 approved indications for its tenapanor (Isbrela for IBS-C and Xphozah for hyperphasphatemia) - probably together worth at least $3 billion at peak sales (Isbrela alone is doing great and it alone is ...
  • Henry: $NVO $LLY WSJ
    The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds competition to a market currently controlled by Eli Lilly and Novo Nordisk , it also reinforces the dominan ...
  • phgruver: @Henry $NVO $LLY All this is interesting, and for for the severely obese, drug intervention may be a necessary first step, but the real solution is something no one wants to talk about. All most people have to do is quit eating junk food. If you keep eating the junk, even these drugs can't help!
  • joelsg1: @woodman $VKTX Chatter that $AMGN had some bad news on its weight-loss drug down $20 fast, good for $VKTX $LLY $NVO.
  • woodman: @joelsg1 $VKTX $AMGN $LLY $NVO - yes, I just saw that. All the competetors seem to have bad news. VKTX continually shows it has the best version. It will move VKTX stock up, but I doubt for long. There are no significant price-moving catalysts on the horizon, and as we know, even good data can have a reverse effect. Moreover, the CEO has made it fairly clear he doesn't intend to commercialize but wants to get it through Phase 3 (which will take a while), so I'd think that's like telling Big Pharma "we have no leverage, so you can wait until price comes way down to buy us."
  • woodman: @joelsg1 $VKTX $AMGN $LLY $NVO - sounds like Cantor finally figured out the bad bone mineral density data on MariTide, which have been available since maybe February. One would think analysts could do a better job of actually reading shit.
  • joelsg1: @woodman $VKTX $AMGN $LLY $NVO Nobody reads carefully anymore, that was my superpower as a lawyer.
  • traderbren: @BarryC $SHAK $SBUX - LOL...not to worry when you start posting about $LLY and $NVO and will understand that you have flipped.
  • BarryC: @traderbren $SHAK $SBUX $LLY $NVO hahahahahaha
  • woodman: $LLY sold a bunch. Getting pounded as collateral damage to $NVO. It will eventually be a buy again for longer term investors - perhaps even soon, but I've sold a bunch to wait and see.
  • joelsg1: @woodman $LLY $NVO Congrats on a big winner!
  • woodman: @joelsg1 $LLY $NVO - Thanks, buddy.
  • traderbren: @woodman $LLY $NVO - good move...looks like $LLY has a huge gap to fill on the downside...in time.
  • woodman: @traderbren $LLY $NVO - sold even more. What was a fairly large position is very small now. That probably means it's a buy now.
  • phgruver: @woodman $LLY $NVO ...Well, the $XLV is up, today, and looks like it might be actionable.... $LLY is 12.76% of the fund, and and it the largest single holding. $NVO is not in the top 10 list.
  • woodman: @phgruver $LLY $NVO $XLV - $LLY now hitting the 100d and ~38.2 Fibonacci Retracement (4/25 to 7/15). Potential bounce spot here.
  • traderbren: $NVO - climbing back over the 200d. Not sure what fireworks will occur with the Senate hearing today regarding price point!
  • woodman: $VKTX - Although VKTX was already moving higher last week and this week, today's move is being ascribed to $NVO announing that it has to do a Phase 2b trial. Conversely, VKTX is allowed to move straight to Phase 3 without a Phase 2b trial. Safety/tolerability of VKTX's rivals have consistently been worse than $VKTX. VKTX is best in class in that department.
  • woodman: @StockMarketMentor $VKTX - Welcome aboard. :-) #ObesityWeek 11/3-11/5, and its Quarterly report in October, are the things to look forward to in terms of fundamentals, but also for traders becasue I see these as potential run-up catalysts. I expect a ...
  • joelsg1: @DavidK $VKTX $LLY and $NVO flat, $GPCR and even $ALT up. I smell a buyout.
  • Bs7518: @woodman $VKTX $RHBBY $NVO #Roche as usual great summary thanks
  • woodman: ...
    $VKTX, on the other hand, has been very transparent, because they know they have the goods - both in terms of efficacy and tolerability/saftey. The FDA's decison to let them proceed right to Phase 3 (skipping over Phase 2B) is huge, IMO. It will cut ...
  • sgiseller: @woodman $VKTX $RHBBY $NVO #Roche I am with you on $VKTX, I'm long and a bit underwater on stock, but have been selling weekly calls and doing rather well
  • woodman: $VKTX $RHBBY $NVO #Roche - One proviso is that I've yet to see evidence that the company is truy prepared to commercialize on its own. I believe it wants to be acquired. I think entering Phase 3 (for subQ) could move it closer to being acquired if an ...
  • sgiseller: @woodman $VKTX $RHBBY $NVO #Roche I believe they are totally short on facilities to mfg, not all that excited about the Nash drug, there have been many co's going after nash, seems like a niche ailment
  • woodman: @sgiseller $VKTX $RHBBY $NVO #Roche - I think management would like to off-load in some way the MASH/NASH so it can focus on obesity. Plus, obesity drugs may well work for MASH/NASH to some degree. If they don't find a way to off-load it, a company buying VKTX for obesity would get it essentially for free.
  • sierramp: @woodman $VKTX $RHBBY $NVO #Roche Thanks for your $VKTX analysis. I have a small spec position. I don't throw my money at the wall hoping something sticks. The risk / reward with $VKTX is better than many. Also stochastic cross, Wms percent R and the July PB.
  • PeterB: @woodman $VKTX $RHBBY $NVO #Roche VKTX was a learning opportunity for me. I went in too big intending it be a day trade and didn't get out. So I'm underwater and have decided to hold position and consider it a long term investment, but not adding at this point.
  • woodman: @PeterB $VKTX $RHBBY $NVO #Roche - Biotech is rough. I have only $VKTX $ARDX and $HUMA right now. The first two are holds (add and hold) for me. HUMA has its PDUFA likely tomorrow. If moves up nicely on an approval, I will sell a bunch the look to buy back after the inevitable move back down. If it is not approved ... look out below.
  • traderbren: $NVO - got close to testing the 200d. NP
  • woodman: @Henry $LLY $NVO $VKTX - Heart, kidney, liver, sleep apnea, alcohol addiction, and on and on.
  • DavidG: @woodman $LLY $NVO $VKTX But the GLP1/GIP field is becoming crowded with new agents being introduced- some promising oral agents. I've been selling option premium on $VKTX rather than own the stock. It whips around so much that occ. you can time put/ BuPS sales.
  • woodman: @DavidG $LLY $NVO $VKTX - I hear you. Every bit of news, even when its sh-t news such as a company like Roche reporting only some data (what it deems favorable) while hiding other data (raising many questions), moves the other stocks. It's the Wild Wild West out there.
  • Henry: $VKTX GLP-1 drug is moving to Phase 3 and is knocking the stuffing out of $NVO & $LLY Sorry I did not see Woodman's earlier post
  • woodman: @Henry $VKTX $NVO $LLY - Here are some really inportant takeaways from yesterday's quarterly call:

    1. Straight to Phase 3, skipping Phase 2b altogether which everyone (including me) thought would be to Phase 2b. It's a wonderful surprise. As I just ...
  • woodman: $LLY $NVO - bye-bye.
  • Mikev200: @woodman $LLY $NVO No kidding...
  • billyzeke: @woodman $LLY $NVO After waking up and seeing it down in the pre-market I was thankful to get out at 847 at the open.
  • woodman: @billyzeke $LLY $NVO - Good job. It's trying to find support now at the 100d / old Feb-May channel resistance, testing the adage: prior resistance serves as new support. Also this drop is a bounce off the 61.8 Fib Retracement.
  • woodman: ...
    One more tidbit about its oral obesity drug. They are now moving to 100mg cohort. What that means is that the high level doses - 60mg, 80mg tested already - are showing good tolerability. The company will keep moving up in mg's until tolerability/AE ...
  • woodman: $LLY and $NVO "bounce-backs" not looking so hot. More like bear flags. In LLY's case, it's barely hanging on to the 50d.
  • DavidG: @Woodman $LLY $NVO -- Latest issue of the New England Journal of Medicine had a nice article showing significant efficacy of tirzepatide (LIlly's drug) for metabolic associated liver disease (MASH) with regression of liver fibrosis (cirrhosis) in a ...
  • woodman: @DavidG $LLY $NVO - Thanks for the info and link. The same should apply for $VKTX's GIP obesity med - VK2735 https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2735/ VKTX also has a separate NASH/MASH candiate - VK2809 - https://vik ...
  • billyzeke: @woodman $LLY $NVO I held my nose and added a little at 855 today, it's finally getting a little traction here. I may just be trading these additional shares, depending on how the day goes.
  • woodman: @billyzeke $LLY $NVO - Tempting, but I will just stand my ground right now. I added on 7/19, and I don't like it enough rhrn as it is still below the 8dEMA and the 21dEMA and is looking wobbly (rollover-ish from yesterday) as it barely holds the 50dSMA. On the other hand, I like the decreasing volume over the last 4 days, including today, with volume yesterday and probably today below its 50d avg of volume. Neverthless, I will just wait and see what happens here. I don't need to buy THE bottom. Rather, I want to feel like it is done going down and buy when it's in a stronger position. This isn't one I'm just in for a quick trade.
  • billyzeke: @woodman $LLY $NVO I ended up selling the shares I bought today at 865 right after I posted that reply. Going to try and hang onto the shares I bought last Thursday at 845, that trade today helped me build in a little cushion.
  • woodman: $LLY $NVO $VKTX - I'm just getting to my desk after a full walkabout of my innards with an endo/colo double-whammy this morning. (Sorry if TMI.) This drop in $LLY and $NVO on #Roche $RHHBY news is ridiculous. First, Roche provided no safety/tolerabil ...
  • Motorman: @woodman $LLY $NVO $VKTX $RHHBY $AMGN #Roche #OT Wow, a round the world, hope all is ok. I did the cologuard.
Visit the Trading Forum to join in the discussion.
Stock Price $50.18
Change -0.22%
Volume 12,373,700

Novo-Nordisk A/S is a healthcare company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company operates in two business segments, diabetes care and biopharmaceuticals.

Request Video of NVO
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!